AquaBounty Technologies Inc. 2016 10-K Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2016. AquaBounty Technologies, Inc. is a biotechnology company focused on the aquaculture market, specifically developing the AquAdvantage Salmon, the first genetically modified animal approved for human consumption. The company received FDA approval in November 2015 and Health Canada approval in May 2016. As of the reporting date, the company had not yet generated revenue from product sales and remains in the pre-commercialization phase, operating facilities in Prince Edward Island, Canada, and Panama.
Key Financial Metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8.47) million | $(7.03) million |
| Operating Loss | $(8.07) million | $(7.03) million |
| Cash and Cash Equivalents (Year End) | $3.32 million | $1.31 million |
| Total Assets | $5.71 million | $2.64 million |
| Total Debt | $2.66 million | $2.07 million |
| Stockholders' Equity | $2.03 million | $(0.06) million |
| Cumulative Deficit (Since Inception) | $(99.3) million | $(90.8) million |
Note: The company reported no revenue for the period. Expenses were primarily driven by Research and Development ($3.43 million) and General and Administrative costs ($3.78 million).
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately 20% (from $7.03 million to $8.47 million) due to higher operating expenses.
- Expense Drivers: General and Administrative expenses rose 40% year-over-year, attributed to increased headcount, legal fees related to regulatory challenges, and costs associated with becoming a U.S. public reporting company. Research and Development expenses increased slightly (3%) due to a shift from contract work to in-house personnel and the commencement of field trials in Argentina and Brazil.
- Balance Sheet Improvement: Total assets more than doubled from $2.64 million to $5.71 million, driven by the purchase of the Rollo Bay farm site in Canada and an increase in cash balances.
- Debt Conversion: A $10.0 million convertible debt facility with Intrexon Corporation was fully converted into common stock in December 2016, eliminating that specific debt obligation but increasing share count.
Guidance, Outlook, and Risks
Outlook and Capitalization: Management expects to continue incurring significant losses for the foreseeable future. While modest revenues could commence as early as Q4 2017 from the Panama farm, significant revenue is not expected until a new North American facility is operational. The company raised approximately $25 million in a private placement with Intrexon in January 2017 (subsequent to year-end) and believes this, combined with existing cash, will fund operations for at least the next 12 months.
Key Risks and Contingencies:
- Regulatory and Legal: A coalition of NGOs has sued the FDA regarding the approval of AquAdvantage Salmon; the case is in the discovery phase. Additionally, an FDA Import Alert remains in effect pending final labeling guidance, which could delay commercial sales.
- Consumer Acceptance: The company faces potential market resistance due to the genetically modified nature of the product and activist pressure on retailers.
- Liquidity: The company has a history of net losses and will require substantial additional capital to fund commercialization and facility construction.
- Intellectual Property: The primary patent for the technology expired in 2013; the company relies on trade secrets and regulatory barriers for protection.
Investor Verification Checklist
- Regulatory Status: Verify the current status of the FDA Import Alert and the outcome of the NGO lawsuit challenging the FDA approval.
- Capital Runway: Confirm the utilization of the $25 million raised in January 2017 and the timeline for the next potential capital raise.
- Commercialization Timeline: Assess the progress of the pilot-scale commercial operation and the search for a North American production facility.
- Debt Obligations: Review the terms of the remaining debt, specifically the ACOA grant (repayable via 10% royalty) and the PEI Finance term loan.
- Share Dilution: Monitor the impact of the 1-for-30 reverse stock split (implemented Jan 2017) and recent equity issuances on shareholder ownership.